XJZY(SZ:002332) Xin Lang Cai Jing·2025-10-17 01:30Core Viewpoint - Xianju Pharmaceutical experienced a slight decline in stock price and notable trading activity, indicating potential investor concerns and market dynamics [1][2]. Financing Summary - On October 16, Xianju Pharmaceutical had a financing buy-in amount of 13.11 million yuan, with a net financing outflow of 2.94 million yuan, reflecting a high financing balance of 567 million yuan, which constitutes 5.81% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of investor engagement [1]. - The company also reported a securities lending situation with a total of 15.31 million shares available for lending, with a balance of 1.51 million yuan, also above the 80th percentile of the past year [1]. Business Performance - For the first half of 2025, Xianju Pharmaceutical reported a revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [2]. - The company's main revenue sources include corticosteroids (63.39%), gynecological and contraceptive drugs (20.69%), other medications (9.21%), and anesthetics and muscle relaxants (6.71%) [1]. Shareholder Information - As of September 30, the number of shareholders for Xianju Pharmaceutical stood at 50,000, with no change from the previous period [2]. - The cumulative cash dividends paid by the company since its A-share listing amount to 2.031 billion yuan, with 989 million yuan distributed over the last three years [3]. - Notably, the Southern CSI 1000 ETF is among the top ten circulating shareholders, increasing its holdings by 1.4094 million shares [3].